LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akcijų sąrašas・Erasca Inc

Erasca Inc

Uždarymo kaina

11.23 -3.44

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.17

Max

11.7

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-154M -183M
Pelnas, tenkantis vienai akcijai	-0.6
Darbuotojai	103
EBITDA	-5.3M -37M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+74.74% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-10

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-53M 3.2B
Ankstesnė atidarymo kaina	14.67
Ankstesnė uždarymo kaina	11.23

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.39 / 1.44 Palaikymas ir pasipriešinimas

Erasca Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-22 16:33; UTC

Uždarbis

Pagrindinės rinkos jėgos

Webull Shares Slide on 1Q Loss, Soaring Costs

2026-05-22 21:10; UTC

Uždarbis

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

2026-05-22 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-22 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-22 19:47; UTC

Uždarbis

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

2026-05-22 19:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

2026-05-22 19:10; UTC

Rinkos pokalbiai

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

2026-05-22 18:54; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-22 18:54; UTC

Rinkos pokalbiai

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

2026-05-22 18:38; UTC

Rinkos pokalbiai

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

2026-05-22 18:35; UTC

Įsigijimai, susijungimai, perėmimai

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

2026-05-22 18:09; UTC

Rinkos pokalbiai

Centralized Crypto Lending Slows in 1Q -- Market Talk

2026-05-22 17:58; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

2026-05-22 17:54; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2026-05-22 17:54; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-22 17:54; UTC

Rinkos pokalbiai

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

2026-05-22 17:03; UTC

Rinkos pokalbiai

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

2026-05-22 16:54; UTC

Rinkos pokalbiai

Crypto Spot Volumes Fall 14% in April -- Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-05-22 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-22 16:16; UTC

Rinkos pokalbiai

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

2026-05-22 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-22 15:55; UTC

Rinkos pokalbiai

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

2026-05-22 15:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-22 15:42; UTC

Rinkos pokalbiai

Oil Continues as Leading Indicator for All Markets -- Market Talk

2026-05-22 15:35; UTC

Rinkos pokalbiai

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Akcijų palyginimas

Kainos pokytis

Erasca Inc Prognozė

Kainos tikslas

By TipRanks

74.74% į viršų

12 mėnesių prognozė

Vidutinis 20.27 USD 74.74%

Aukščiausias 30 USD

Žemiausias 9 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Erasca Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Erasca Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.39 / 1.44Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.